BioLight Israel Life Sciences Investments Ltd.

www.bio-light.co.il

Holding Company
Public Company

(TASE: BOLT)

Tech Verticals Preferences

Medical Devices, MedTech

General Data

Established	2005
Current Active Portfolio Companies:	8
Reg. Number:	abCDe

DESCRIPTION

BioLight invests in, manages and commercializes biomedical innovations grouped into “clusters” around defined medical conditions. The two current clusters are in ophthalmology via 100% ownership of XLVision Sciences, and in cancer diagnostics via a 29% controlling ownership of Micromedic. XLVision technologies include IOPtimate, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designated for colorectal, cervical, breast, bladder, lung and other cancers.

BioLight is a public company traded on the Tel Aviv Stock Exchange (BOLT) and on the OTCQX (BLGTY).

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
CA7DE34A-207A-E111-AC59-00155D32A403		BioLight Israel Life Sciences Investments Ltd.
205E0C4F-E60F-E311-924B-00237DE91982	Subsidiary	Visci Ltd. (Eye-D)	BioLight Israel Life Sciences Investments Ltd.
769B143E-0A35-EE11-B812-00505695CD29	Subsidiary	Lipicare Pharmaceuticals Ltd. (BioLight Life Sciences)	BioLight Israel Life Sciences Investments Ltd.

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Investment Bank

REMARKS

Date	Remark
21/06/2012	BioLight acquired an ocular implant for sustained release of drugs for the treatment of glaucoma from a US company. IOptima's R&D team will be responsible for development of the ocular implant.
01/04/2011	A group led by Mr. Israel Makov gained control in the company introducing ‎a new approach of value creation through knowledge synergies (the clusters approach).

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	Kiryat Atidim, Bldg. 3, 5th Floor
City	Tel Aviv
Country	Israel
Zip	6158101

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Israel Makov	Chairman	Teva (CEO)
Mr. Yaacov Michlin	CEO	Yissum (President & CEO)
Ms. Suzana Nahum-Zilberberg	Vice Chairman	Teva (VP China, India and South East Asia)
Mr. Shmuel Perets	Director
Mr. Eli Shohet	Director

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Sep. 21, 2025	Eighth Public Offering		abCDe	abCDe	Raised NIS 20m; Valuation NIS 40m
Mar. 05, 2014	Seventh Public Offering	TASE	abCDe	abCDe
Nov. 04, 2012	Sixth Public Offering	TASE	abCDe	abCDe	Israel Makov, Shangvi Dilip and Dexcel Pharma each bought shares for the amount of $2m as part of this public offering.
Jun. 28, 2010	Fifth Public Offering	TASE	abCDe	abCDe
Dec. 09, 2009	Fourth Public Offering	TASE	abCDe	abCDe
May. 17, 2009	Third Public Offering	TASE	abCDe	abCDe
May. 31, 2006	Second Public Offering	TASE	abCDe	abCDe	Convertible Debentures
Dec. 22, 2005	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Apr. 01, 2015

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Holding Company	abCDe	Holds 19% of the company. As part of the strategic partnership, the parties will also form a Joint Venture. The newly formed JV will be fully financed by Rock-One and granted exclusive manufacturing rights for BioLight's products distributed within China.

PIPE

Apr. 06, 2014

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Institutional Investor	abCDe	Holds 3.5% of the company.
abC Defghij	Institutional Investor	abCDe	Holds 11.9% of the company.
abC Defghij	Investment Bank	abCDe	Holds 5.8% of the company.

PIPE

Feb. 23, 2011

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe	Holds 24% of the company's shares with additional warrants that will lead to 48% of the company.

PIPE

Mar. 08, 2007

Initial Revenues

abCDe

Other

Jan. 01, 2005

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe	Holdings sold.
abC Defghij	Private Investor	abCDe	Holds 15.3% of the company.
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe	17%, $3m
abC Defghij	Private Investor	abCDe	Holdings sold.

Investment Data

Managed Capital

abCDe

Capital Remarks

12/2005: Raised $4.4m from the public. 05/2006: Raised $6.75m from the public. 03/2007: Raised $4.75m in a PIPE from Menorah Mivtachim. 05/2007: Raised $2m in a PIPE from Gmulot & Others 05/2009: Raised $1.8m from the public. 12/2009: Raised $3.1m from the public. 06/2010: Raised $1.3m from the public. 01/2011: Raised 0.25 m$ in privet offering 04/2011: Raised $3.4m in private offering 09/2011: Raised $3.1m in private offering

Preferences

Type of Financing	Equity,In-Licensing
Stage Preferences	Initial Revenues,R&D,Revenue Growth,Seed
Phase Preferences	Clinical Trials,Phase I,Phase II,Phase III

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

57%

Medical Devices

29%

Digital Health

14%

	PORTFOLIO COMPANIES

Current Portfolio Companies (8)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

AEYE

Dig. Health

First Round

05/04/2022

$1m

$10m

BioLight has the option for an additional investment of up to $1.5m, after which BioLight's holding is expected to increase to approximately 10%

BioLight Life Sciences

Biomed

Seed

09/06/2016

N/A

DiagnosTear

Biomed

First Round	15/10/2020	$1m	$3.85m	DiagnosTear is held by XL Vision which is fully owned by BioLight.
Seed	01/01/2013	N/A	N/A	DiagnosTear is held by XL Vision which is fully owned by BioLight.

Micromedic

N/A

PIPE	18/02/2013	$0.8m	$3.8m
PIPE	17/04/2012	$1.066m	$1.066m
PIPE	21/11/2011	N/A	N/A	Biolight purchased 20.6% of the company (and gained control of it) in exchange for 100% Zetiq shares.

OphRx

Biomed

Seed

01/01/2015

N/A

$1m

Sanoculis

Second Round	28/07/2022	$0.6m	$14m	0.1m was originally a convertible loan given in August 2021 and is now converted into equity.
First Round	01/12/2019	N/A	$1.1m

Tarsier Pharma

Biomed

Second Round

03/10/2019

$1m

N/A

Visci

Seed

01/06/2011

N/A

BioLight holds 100% of the company through XL Vision Ltd.

Exits (2)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	05/05/2024	abCDe	An immediate consideration of $81m, with a possible total consideration of approximately $385m, depending on achieving certain milestones.
abC Defghij	Acquired	21/11/2017	abCDe	The deal will take place in four stages, with Chengdu Kanghong investing $7m at a company value of $30m, before money, in the first stage. In the next stage, it will buy shares from IOPtima's existing shareholders, including BioLight, which has a 70% stake. If all of the stages are exercised, IOPtima will be sold at a $56m value, to be paid gradually by 2021.

Historic Portfolio (3)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Allergica

Ceased to Operate

Biomed

Seed

01/06/2005

$2m

Held 100% of the company

ObCure

Ceased to Operate

Biomed

Seed

01/06/2005

$2.9m

Held 91.3% of the company

Zetiq

Ceased to Operate

Biomed

Third Round

01/06/2005

$1m

09/2011: Holdings through Micromedic Technologies Ltd. BioLight's shares in Zetiq were transferred to Micromedic in exchange for Micromedic's shares.

Last Updated:	abCDe
IVC Number:	abCDe